Monte Rosa Therapeutics is a clinical-stage biotech developing molecular glue degraders (MGDs) — small molecules that force disease-causing proteins to bind with an E3 ubiquitin ligase enzyme, tagging those proteins for destruction by the cell's natural disposal machinery. This approach allows Monte Rosa to target proteins with no suitable binding pocket, which are "undruggable" by conventional small molecules. Monte Rosa's pipeline spans immunology and oncology, with three programs in active clinical development. MRT-6160 targets VAV1, a protein driving T- and B-cell activation in autoimmune diseases, and has been licensed globally to Novartis, which leads development from Phase 2 onwards. MRT-8102 targets NEK7, a scaffolding protein essential for the NLRP3 inflammasome, which drives inflammatory conditions including cardiovascular disease and gout; Monte Rosa is developing this program independently and plans Phase 2 studies in 2026-2027. MRT-2359 targets GSPT1 in MYC-driven prostate cancer and is headed toward a Phase 2 study in 2026. Monte Rosa generates revenue through licensing deals with large pharma partners, including Novartis and Roche, receiving upfront payments, contingent milestone payments, and royalties or profit-sharing on commercialized products. Monte Rosa's core discovery asset is its QuEEN platform, which uses AI/ML, high-throughput screening, structural biology, and proteomics to identify and design MGD molecules against previously undruggable targets. The QuEEN platform is both the basis for Monte Rosa's own pipeline and the licensed asset that attracts pharma partnerships.